cat 179 catamaran bio

Catamaran Pipeline

Of CAR-NK cell therapies

We are rapidly advancing our CAR-NK cell therapies toward the clinic to address solid tumors.

Lead programs, cat-248: cd70 car-nk cell therapy.

CAT-248 is our off-the-shelf CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70; an IL-15 cytokine that promotes persistence and enhanced NK cell activity, a TME-switch that neutralizes the effects of the TGFβ immunosuppressive signal found in the tumor microenvironment, and the elimination of CD70 expression to enable scalable manufacturing. Our initial clinical studies with CAT-248 will target renal cell carcinoma.

CAT-179: HER2 CAR-NK Cell Therapy

CAT-179 is our off-the-shelf CAR-NK cell therapy targeting HER2 positive solid tumors. CAT-179 has been engineered with three functional modifications: an optimized CAR that targets HER2, an IL-15 cytokine  that promotes persistence and enhanced NK cell activity, and a TME-switch that neutralizes the effects of the TGFβ immunosuppressive signal found in the tumor microenvironment. Our initial clinical studies with CAT-179 will target breast cancer and gastric cancer.

Research Pipeline

We are deploying our modular TAILWIND ® platform to develop additional CAR-NK therapies for solid tumors by leveraging our suite of innovative TME switches, optimized CAR architecture, and versatile manufacturing platform.

Catamaran contact: Mark Boshar, Chief Operating Officer 617-620-9709 [email protected]

Media Contact: Kathryn Morris, The Yates Network 914-204-6412 [email protected]

Release Summary

Social media profiles.

• Catamaran Bio/Twitter
• Catamaran Bio/LinkedIn

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Premium News
• Biden Economy
• EV Deep Dive
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Personal Loans
• Student Loans
• Car Insurance
• Morning Brief
• Market Domination
• Market Domination Overtime
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Catamaran bio announces preclinical data from allogeneic car-nk cell therapy pipeline for solid tumors to be presented at the american association for cancer research (aacr) annual meeting 2023.

Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models

Data underscore potential of TAILWIND ® platform to create effective CAR-NK treatments for solid tumors

BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Catamaran Bio , Inc., a biotechnology company developing off-the-shelf natural killer (NK) cell therapies to treat cancer, today announced new data demonstrating preclinical pharmacology and in vivo efficacy from the Company’s two CAR-NK cell therapies in solid tumors have been selected for poster presentations during the American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.

“The data we’ll share at AACR demonstrate the strength of our TAILWIND ® platform to design and manufacture highly effective, unique and differentiated CAR-NK products,” said Vipin Suri, PhD, MBA, Chief Scientific Officer of Catamaran Bio. “We can efficiently manufacture multi-functional CAR-NK products which have demonstrated significant efficacy in solid tumor xenograft models. These advances are part of our continuing progress toward the clinic and lay the foundation for our first in-human studies in solid tumors to begin in 2024.”

Both posters will be presented on Monday, April 17, 2023, from 1:30-5:00 p.m. ET during the PO.IM01.02 - Natural Killer and Natural Killer T Cell-based Cellular Therapies poster session. Details of the presentations are as follows:

CAT-248, an allogeneic CD70-directed CAR-NK cell therapy effectively controls CD70-positive tumor xenografts

Highlights from the presentation supporting Catamaran’s lead program, CAT-248, include:

Demonstration that CAT-248 significantly reduces growth of 786-O renal cell carcinoma xenografts in both intraperitoneal and subcutaneous in vivo models

Use of a novel, single-step engineering solution for simultaneous, non-viral delivery of a CAR, TGFβ dominant-negative receptor (DNR) and secreted IL-15 in combination with CRISPR/Cas9 knockout of CD70 in primary human peripheral blood NK cells to prevent fratricide

Evidence that the incorporation of a TGFβ DNR provides protection from TGFβ-mediated immunosuppression

The use of secreted IL-15 leads to enhanced NK cell persistence

These data establish CAT-248 as a highly differentiated CAR-NK cell therapy with the potential to provide durable responses in renal cell carcinoma and other CD70-expressing cancers.

CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice

Highlights of data from Catamaran’s second CAR-NK cell therapy construct engineered using its TAILWIND ® platform include:

Demonstration that a single dose of TAILWIND ® -engineered CAR-NK cells induces durable regression in multiple HER2 xenograft models

Functional persistence is conferred by the components engineered into the cell (TGFβ DNR and secreted IL-15) via the TAILWIND ® process

Engineered NK cells effectively infiltrate tumor tissue

Novel PK/PD analysis demonstrating a direct linkage between NK cell numbers, IL-15 levels and efficacy

These results demonstrate the ability of CAT-179 to infiltrate and regress tumors in multiple in vivo models, and support further development of CAT-179 for the treatment of HER2+ solid tumors.

Both posters will be available on the Catamaran Bio website upon commencement of the meeting.

About Catamaran Bio Catamaran Bio  is developing novel, off-the-shelf chimeric antigen receptor-natural killer (CAR-NK) cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our  TAILWIND ® platform , an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management and the UMN Discovery Capital investment program. For more information, please visit  www.catamaranbio.com  and follow us on  LinkedIn  and  @CatamaranBio  on Twitter.

Catamaran Contact: Michael DeRidder, PhD, SVP Corporate Strategy 267-496-6534 [email protected]

Media Contact: Gina Cestari 6 Degrees 917-797-7904 [email protected]

Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR‑NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catamaran Bio , Inc., a biotechnology company developing off‑the-shelf NK cell therapies to treat cancer, today announced that the company will present preclinical efficacy data for its allogeneic, cryopreserved CAR-NK cell therapies designed to treat solid tumors, engineered using Catamaran’s TAILWIND TM platform. The data demonstrate the promise of two of the company’s CAR-NK cell therapies, CAT-248 and CAT-179, for the treatment of solid tumors, and will be presented in two poster presentations at the Society for Immunotherapy in Cancer (SITC) 37 th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022.

Details of the poster presentations are as follows:

Title for CAT-248 poster: Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies

• Lead Authors: Branden Moriarity, PhD, Associate Professor, Division of Hematology/ Oncology and Jae-Woong Chang, PhD, Research Associate, University of Minnesota (research agreement sponsored by Catamaran Bio); Eugene Choi, Principal Scientist, Catamaran Bio
• Session Date and Time: November 11, 2022, 9:00 a.m. - 8:30 p.m.
• Location: Poster Hall
• Abstract Number: 392

Title for CAT-179 poster: Allogeneic natural killer cells engineered to express HER2-directed CAR, interleukin-15 and TGFß dominant negative receptor effectively control HER2+ tumors

• Lead Author: Finola Moore, PhD, Director, Catamaran Bio
• Abstract Number: 264

Both abstracts will become available online on the SITC conference website beginning at 8:00 a.m. ET on Monday, November 7, 2022.

About Catamaran Bio

Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWIND™ platform , an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management, and the UMN Discovery Capital investment program. For more information, please visit www.catamaranbio.com and follow us on LinkedIn and @CatamaranBio on Twitter.

Catamaran contact: Mark Boshar, Chief Operating Officer 617-620-9709 [email protected] Media Contact: Kathryn Morris, The Yates Network 914-204-6412 [email protected]

Editor Details

• Businesswire

You are leaving PharmiWeb.com

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

CAT-179 / Catamaran Bio - LARVOL DELTA

Spinner flask modelling of wave-style bioreactors enables suspension-phase cell culture process development of allogeneic car-nk cell therapies (asgct 2023) - "two distinct car-nk products, cat-179 and cat-248, were produced in three different culture systems: 150ml spinner flasks, 1l static cultures and 2l wave-style bioreactors. use of the model revealed that the optimization of this parameter is critical to maximizing the yield of potent drug products in the cat-248 process.¶in summary, our data demonstrates proof of concept for the use of spinner flasks for culturing nk cells, providing a small-scale platform to model a wave-style suspension culture process more accurately. use of this model will expedite scale-up process development as we pursue our clinical goals, shortening the path to clinical readiness and supplying a more complete data package in support of the clinical manufacturing of multiplex-engineered nk cells for solid tumor applications.", preclinical • hematological disorders • hematological malignancies • oncology • solid tumor.

• More sharing Reddit StumbleUpon Delicious

CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice (AACR 2023) - "Efficacy strongly correlated with the circulating levels of CAT-179, which significantly infiltrated the tumor xenograft. Our pre-clinical results demonstrate the potential of CAT-179 as a novel, durable, and off-the-shelf cell therapy to overcome the challenges associated with solid tumors and provide quantitative insights into pharmacokinetics, pharmacodynamics and anti-tumor activity of engineered NK cells expressing CAR, TGFb DNR and IL-15."

Preclinical • gastric cancer • gastrointestinal cancer • hematological malignancies • oncology • ovarian cancer • solid tumor • her-2 • il15 • tgfb1, catamaran bio announces preclinical data from allogeneic car-nk cell therapy pipeline for solid tumors to be presented at the american association for cancer research (aacr) annual meeting 2023 (globenewswire) - "catamaran bio, inc...announced new data demonstrating preclinical pharmacology and in vivo efficacy from the company’s two car-nk cell therapies in solid tumors have been selected for poster presentations during the american association for cancer research (aacr) annual meeting taking place april 14-19, 2023, at the orange county convention center in orlando, fl....'these advances are part of our continuing progress toward the clinic and lay the foundation for our first in-human studies in solid tumors to begin in 2024'....demonstration that cat-248 significantly reduces growth of 786-o renal cell carcinoma xenografts in both intraperitoneal and subcutaneous in vivo models....demonstration that a single dose of tailwind ® -engineered car-nk cells induces durable regression in multiple her2 xenograft models.", new trial • preclinical • genito-urinary cancer • kidney cancer • oncology • renal cell carcinoma • solid tumor, allogeneic natural killer cells engineered to express her2-directed car, interleukin-15 and tgfß dominant negative receptor effectively control her2+ tumors (sitc 2022) - "cat-179 effectively reduced skov-3-luc tumor burden in nsg mice (95% auc, p<0.0001 for survival). conclusions cat-179 is a promising demonstration of the catamaran car-nk platform, as a novel off-the-shelf cell therapy to overcome the challenges associated with solid tumors.", gastric cancer • gastrointestinal cancer • hematological malignancies • oncology • ovarian cancer • solid tumor • her-2 • ifng • il15 • tnfa, catamaran bio presents preclinical efficacy data for two allogeneic car-nk cell therapies for solid tumors at sitc 2022 annual meeting (businesswire) - "data from a second car-nk cell therapy construct engineered using the tailwind™ platform are presented in a poster...highlights include...cat-179 demonstrated her2-car-driven interferon gamma (ifnγ) production and tumor cell killing in vitro when co-cultured with her2+ tumor cells; cat-179 was resistant to tgfβ-mediated immunosuppression in vitro, indicating that the cells will be protected from tgfβ-mediated immune suppression in the tumor microenvironment; engineering of il15 in cat-179 significantly enhanced nk cell persistence and in vitro and in vivo and eliminated the need for exogenous cytokine support; cat-179 showed potent anti-tumor activity in vivo against a xenografted her2+ n87 gastric cancer cell line and led to a significant survival benefit in tumor-bearing mice.", preclinical • gastric cancer • gastrointestinal cancer • oncology • solid tumor, catamaran bio to present preclinical efficacy data for allogeneic car‑nk cell therapies to treat solid tumors at sitc annual meeting (businesswire) - "catamaran bio, inc...announced that the company will present preclinical efficacy data for its allogeneic, cryopreserved car-nk cell therapies designed to treat solid tumors, engineered using catamaran’s tailwind tm platform. the data demonstrate the promise of two of the company’s car-nk cell therapies, cat-248 and cat-179, for the treatment of solid tumors, and will be presented in two poster presentations at the society for immunotherapy in cancer (sitc) 37th annual meeting, being held in boston, massachusetts, november 8-12, 2022.", preclinical • hematological malignancies • oncology • solid tumor, allogeneic natural killer cells engineered to express her2 car, interleukin 15 and tgf beta dominant negative receptor effectively control her2+ tumors (aacr 2022) - "moreover, cat-179 administration to nsg mice showed expansion and persistence of the transferred cell product. cat-179 addresses key hurdles to allogeneic cell therapy for solid tumors and is a promising new therapeutic approach for her2 expressing breast, gastric and other tumors.", gastric cancer • gastrointestinal cancer • hematological malignancies • oncology • solid tumor • her-2 • il15 • tgfb1, catamaran bio presents preclinical in vivo efficacy data supporting advancement of cat‑179, a her2-targeted allogeneic car-nk cell therapy (businesswire) - "cat-179 demonstrated her2-car-driven interferon gamma production and tumor cell killing in vitro when co-cultured with her2+ tumor cells. the tgfβ dnr in cat-179 demonstrated resistance to tgfb-mediated immunosuppression in vitro. cat-179 cells persisted in vitro without the need for exogenous cytokines and showed significantly enhanced in vivo persistence up to at least 40 days in mouse models. cat-179 showed potent anti-tumor activity against a xenografted her2+ ovarian cancer cell line (skov3), leading to a substantial survival benefit in tumor-bearing mice. overall, cat-179 treated animals demonstrated tumor reduction of 98% compared to control animals (p, preclinical • oncology • solid tumor, catamaran bio to present preclinical efficacy data on allogeneic solid tumor car-nk program at aacr annual meeting 2022 (businesswire) - "catamaran bio...announced that the company will present preclinical efficacy data for its cat-179 program, an allogeneic solid tumor car-nk cell therapy, at the american association for cancer research (aacr) annual meeting 2022, being held in new orleans, louisiana, april 8-13, 2022. cat-179 is an allogeneic, cryopreserved her2-targeted car-nk cell therapy engineered using catamaran’s tailwind platform.", catamaran bio announces lead car-nk cell therapy programs and upcoming data presentation at ash 2021 (businesswire) - "catamaran’s car-nk programs include cat-179 targeting her2-expressing breast and gastric cancers, and cat-248 targeting cd70-expressing cancers....catamaran bio...today announced that it has designated cat-179, a her2-targeted car-nk cell therapy, and cat-248, a cd70-targeted car-nk cell therapy, as its first preclinical development programs. the company also announced that data supporting the cat-248 program will be presented during a poster session at the 63rd annual meeting of the american society of hematology (ash) which will be held virtually and in person in atlanta from december 11-14, 2021.", preclinical • breast cancer • gastric cancer • gastrointestinal cancer • hematological malignancies • oncology • solid tumor.

Copyright ©  2024 - LARVOL. All Rights Reserved. | Privacy Policy | Contact Us | Login

LARVOL 548 Market St, Suite 44120, San Francisco, CA 94104

Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT‑179, a HER2-targeted Allogeneic CAR-NK Cell Therapy

Tags:   preclinical   cell therapy  , – cat-179 significantly reduces tumor burden and extends survival in a mouse her2+ xenograft model –, boston--(business wire)--catamaran bio, inc., a biotechnology company developing allogeneic, off‑the-shelf chimeric antigen receptor (car)-nk cell therapies to treat cancer, today announced preclinical data showing that cat-179, a cryopreserved, allogeneic her2-targeted car-nk cell therapy, reduces tumor burden and extends survival in a her2 mouse xenograft model. the results will be presented at the american association for cancer research (aacr) annual meeting being held in new orleans from april 8‑13, 2022., “with these results, cat-179 exemplifies the industry-leading capabilities of our tailwind platform to engineer off-the-shelf car-nk cell therapies with the features to overcome critical barriers to treat solid tumors,” said vipin suri, phd, mba, chief scientific officer of catamaran bio. “we are successfully integrating nk cell engineering with scalable and efficient cell processing and manufacturing to deliver on the promise of off-the-shelf car-nk cell therapies for solid tumors, and we are excited to be rapidly advancing cat-179 toward the clinic.”, data presented in a poster titled, “allogeneic natural killer cells engineered to express her2 car, interleukin 15, and tgf beta dominant negative receptor effectively control her2+ tumors,” describe experiments showing key capabilities of the tailwindtm platform and characterization of the her2-targeted car-nk cells. highlights from the preclinical results include:, the poster is available on the publications and presentations section of the catamaran bio website., about catamaran bio, catamaran bio is developing novel, off-the-shelf chimeric antigen receptor (car)-nk cell therapies designed to treat a broad range of cancers, including solid tumors. our proprietary capabilities enable us to harness the natural cancer-fighting properties of nk cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. we are using our tailwind™ platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing nk cells and rapidly advance our pipeline of car-nk cell therapy programs. our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in nk cell biology, engineering, manufacturing and clinical application. catamaran is backed by leading financial and corporate investors, including sv health investors, sofinnova partners, lightstone ventures, takeda ventures, astellas venture management, and the umn discovery capital investment program. for more information, please visit www.catamaranbio.com and follow us on linkedin and @catamaranbio on twitter., catamaran contact: mark boshar, chief operating officer 617-620-9709 [email protected], media contact: kathryn morris, the yates network 914-204-6412 [email protected].

Portfolio News

Sofinnova Capital

Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Related Strategy

Related Deal lead

Related Company

Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models

Data underscore potential of TAILWIND® platform to create effective CAR-NK treatments for solid tumors

BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Catamaran Bio Inc ., a biotechnology company developing off-the-shelf natural killer (NK) cell therapies to treat cancer, today announced new data demonstrating preclinical pharmacology and in vivo efficacy from the Company’s two CAR-NK cell therapies in solid tumors have been selected for poster presentations during the American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.

“The data we’ll share at AACR demonstrate the strength of our TAILWIND® platform to design and manufacture highly effective, unique and differentiated CAR-NK products,” said Vipin Suri, PhD, MBA, Chief Scientific Officer of Catamaran Bio. “We can efficiently manufacture multi-functional CAR-NK products which have demonstrated significant efficacy in solid tumor xenograft models. These advances are part of our continuing progress toward the clinic and lay the foundation for our first in-human studies in solid tumors to begin in 2024.”

Both posters will be presented on Monday, April 17, 2023, from 1:30-5:00 p.m. ET during the PO.IM01.02 - Natural Killer and Natural Killer T Cell-based Cellular Therapies poster session. Details of the presentations are as follows:

CAT-248, an allogeneic CD70-directed CAR-NK cell therapy effectively controls CD70-positive tumor xenografts

Highlights from the presentation supporting Catamaran’s lead program, CAT-248, include:

• Demonstration that CAT-248 significantly reduces growth of 786-O renal cell carcinoma xenografts in both intraperitoneal and subcutaneous in vivo models
• Use of a novel, single-step engineering solution for simultaneous, non-viral delivery of a CAR, TGFβ dominant-negative receptor (DNR) and secreted IL-15 in combination with CRISPR/Cas9 knockout of CD70 in primary human peripheral blood NK cells to prevent fratricide
• Evidence that the incorporation of a TGFβ DNR provides protection from TGFβ-mediated immunosuppression
• The use of secreted IL-15 leads to enhanced NK cell persistence

These data establish CAT-248 as a highly differentiated CAR-NK cell therapy with the potential to provide durable responses in renal cell carcinoma and other CD70-expressing cancers.

CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice

Highlights of data from Catamaran’s second CAR-NK cell therapy construct engineered using its TAILWIND® platform include:

• Demonstration that a single dose of TAILWIND®-engineered CAR-NK cells induces durable regression in multiple HER2 xenograft models
• Functional persistence is conferred by the components engineered into the cell (TGFβ DNR and secreted IL-15) via the TAILWIND® process
• Engineered NK cells effectively infiltrate tumor tissue
• Novel PK/PD analysis demonstrating a direct linkage between NK cell numbers, IL-15 levels and efficacy

These results demonstrate the ability of CAT-179 to infiltrate and regress tumors in multiple in vivo models, and support further development of CAT-179 for the treatment of HER2+ solid tumors.

Both posters will be available on the Catamaran Bio upon commencement of the meeting.

About Catamaran Bio

Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor-natural killer (CAR-NK) cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWIND® platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management and the UMN Discovery Capital investment program. For more information, please visit www.catamaranbio.com and follow us on LinkedIn and @CatamaranBio on Twitter. Catamaran Contact: Michael DeRidder, PhD, SVP Corporate Strategy 267-496-6534 [email protected]

Media Contact Gina Cestari 6 Degrees 917-797-7904 [email protected]

Join our mailing list

Keep up to date with our latest news.

Related News

May Health Raises $25 Million in Series B Funding to Advance Development for Ovarian Rebalancing Therapy

Gensight biologics announces a successful offering for an amount over €9.2 million, mediar advances first-in-class fibrosis portfolio to the clinic with first cohort dosing in phase 1 trial of mtx-463 and establishes clinical advisory board, calliditas announces positive topline results of phase 2 head and neck cancer trial with lead nox inhibitor candidate, setanaxib, amolyt pharma granted fda fast track designation for eneboparatide for the treatment of hypoparathyroidism, sofinnova’s newest partners discuss their career paths.